2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1317

Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1150

Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1216

Odontoid Fractures in the Elderly: An Unknown Osteoporotic Fracture?

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1779

Off-Label Use of Biological Therapies in Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1550

One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1548

Opioid Use in Patients with Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1313

Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1190

Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride

Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

9:00AM-11:00AM: Abstract Number: 1227

Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1250

Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1335

p62/SQSTM1 Modulates Bone Erosions in a Murine Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1678

Pathogenic Mechanisms of Esophageal Peristaltic Dysfunction By High Resolution Manometry in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1192

Patient Characteristics That Predict the Effect of Laparoscopic Adjustable Gastric Band Weight Loss Surgery on Knee Osteoarthritis Pain

Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

9:00AM-11:00AM: Abstract Number: 1393

Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1273

Patient Health Questionnaire-9 Utilization for the Detection of Depression in Adolescents and Young Adults with Lupus Nephritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].